Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Phase 1

Terminated

Conditions: Colorectal Cancer
Ovarian Neoplasms
Pancreatic Adenocarcinoma
Renal Cell Carcinoma
Non-small Cell Lung Cancer

Interventions: Drug: RO7515629
Drug: tocilizumab

First Posted Date: 2023-03-15

Last Posted Date: 2024-07-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 3

Registration Number: NCT05769959

Locations: 🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

Phase 1

Terminated

Conditions: Chronic Hepatitis B

Interventions: Drug: RO7565020
Other: Placebo
Drug: Nucleos(t)ide analogue (NUC) treatment

First Posted Date: 2023-03-10

Last Posted Date: 2025-01-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 60

Registration Number: NCT05763576

Locations: 🇺🇸
Quest Clinical Research, San Francisco, California, United States
🇫🇷
Hôpital Saint-Antoine, Paris, France
🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong

and more 9 locations

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 in Participants With Multiple Sclerosis.

Phase 1

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: RO7121932 IV - SAD
Drug: RO7121932 SC - SAD
Drug: RO7121932 - MAD

First Posted Date: 2023-01-30

Last Posted Date: 2025-05-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 129

Registration Number: NCT05704361

Locations: 🇪🇸
Hospital Universitari Vall dHebron (CEMCAT), Barcelona, Spain
🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
Yale University Multiple Sclerosis Center, New Haven, Connecticut, United States

and more 29 locations

Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice

Phase 2

Terminated

Conditions: Cancer

Interventions: Device: Roche DPM Module
Other: Local SOC support
Drug: Atezolizumab SC

First Posted Date: 2023-01-23

Last Posted Date: 2025-02-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 49

Registration Number: NCT05694013

Locations: 🇦🇺
Concord Repatriation General Hospital, Sydney, New South Wales, Australia
🇦🇺
Sunshine Coast University Hospital, Birtinya, Queensland, Australia
🇩🇪
MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -, Stade, Germany

and more 11 locations

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

Phase 2

Active, not recruiting

Conditions: Huntington Disease

Interventions: Drug: Tominersen 60 mg
Drug: Placebo
Drug: Tominersen 100 mg

First Posted Date: 2023-01-17

Last Posted Date: 2025-05-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 301

Registration Number: NCT05686551

Locations: 🇺🇸
Uab Medicine, Birmingham, Alabama, United States
🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸
University of California Davis Medical System, Sacramento, California, United States

and more 69 locations

A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

Phase 2

Active, not recruiting

Conditions: PD-L1-selected Solid Tumors

Interventions: Drug: Tiragolumab and Atezolizumab IV FDC

First Posted Date: 2022-12-22

Last Posted Date: 2025-04-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 60

Registration Number: NCT05661578

Locations: 🇺🇸
Medical Oncology Associates, Spokane, Washington, United States
🇨🇳
Chongqing Sanxia Central Hospital, Chongqing City, China
🇨🇳
Tianjin Cancer Hospital, Tianjin, China

and more 35 locations

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Inavolisib
Drug: Fulvestrant
Drug: Alpelisib

First Posted Date: 2022-12-12

Last Posted Date: 2025-04-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 400

Registration Number: NCT05646862

Locations: 🇦🇷
Clinica Viedma S.A., Viedma, Argentina
🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou City, China
🇨🇳
Sir Run Run Shaw Hospital Zhejiang University, Hangzhou City, China

and more 180 locations

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Phase 2

Active, not recruiting

Conditions: Urothelial Cancer

Interventions: Drug: Atezolizumab
Drug: Tobemstomig
Drug: Tiragolumab

First Posted Date: 2022-12-09

Last Posted Date: 2025-05-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 204

Registration Number: NCT05645692

Locations: 🇩🇰
Aarhus Universitetshospital, Aarhus N, Denmark
🇬🇧
Royal Marsden Hospital, London, United Kingdom
🇬🇧
Royal Preston Hosptial, Preston, United Kingdom

and more 58 locations

A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema

Phase 3

Active, not recruiting

Conditions: Uveitic Macular Edema

Interventions: Drug: Vamikibart
Other: Sham

First Posted Date: 2022-12-08

Last Posted Date: 2025-03-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 245

Registration Number: NCT05642312

Locations: 🇵🇹
Hospital de Santa Maria, Lisboa, Portugal
🇨🇳
Ren Min Hospital Affiliated Wu Han University, Wuhan, China
🇮🇱
Rambam Medical Center, Haifa, Israel

and more 78 locations

Vamikibart in Participants With Uveitic Macular Edema

Phase 3

Active, not recruiting

Conditions: Uveitic Macular Edema

Interventions: Drug: Vamikibart
Other: Sham

First Posted Date: 2022-12-08

Last Posted Date: 2025-05-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 256

Registration Number: NCT05642325

Locations: 🇮🇳
Sankara Nethralaya, Chennai, Tamil NADU, India
🇮🇳
L V Prasad Eye Institute, Hyderabad, Telangana, India
🇺🇸
Associated Retina Consultants, Phoenix, Arizona, United States

and more 90 locations

Home Terms & Conditions Privacy Policy